Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Executive Summary
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
You may also be interested in...
Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Cheplapharm Benefits As Takeda Sheds More Older Products
Japanese major presses on with post-Shire divestments even after passing strategic target.